QUEBEC CITY, Jan. 5, 2012 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life sciences company that develops and commercializes high-value cancer diagnostic tests, announced today that the Company will release its fourth quarter and fiscal 2011 year end results on January 16, 2012, at approximately 4:00 p.m. (ET). This release will be followed by a conference call, which will be held on the same day, at 4:30 p.m. (ET). The conference will begin with a brief presentation, followed by a question-and-answer period.
The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences.
For those who wish to take part in the conference call for the Q&A period, please dial the phone number, provide the subject "DiagnoCure Q4 Earnings announcement" and the Conference ID: 4500830. Access phone numbers for participants from Montreal, is 514-807-8791 and for other participants the toll-free number is 1-800-731-5319.
For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of January 17, 2012, also through a link on the Investors page - Presentations and Conferences.
DiagnoCure (TSX: CUR) is a life sciences company that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Company launched the PrevistageTM GCC Colorectal Cancer Staging Test through its U.S. CLIA laboratory, and granted the worldwide exclusive rights to this test to Signal Genetics in June 2011. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. The PROGENSA® PCA3 test is commercialized en Europe under CE mark and was recently approved in Canada; in the United States, the test is commercialized through clinical laboratories using PCA3 analyte specific reagents from Gen‐Probe; a PMA application was filed with the FDA. For more information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. The forward-looking statements regarding the outcome of research and development projects, clinical studies and future revenues are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.
For further information: